Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Rockwell Medical (RMTI) EBITDA (2016 - 2025)

Historic EBITDA for Rockwell Medical (RMTI) over the last 17 years, with Q3 2025 value amounting to -$1.6 million.

  • Rockwell Medical's EBITDA fell 18181.82% to -$1.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$4.8 million, marking a year-over-year decrease of 92965.52%. This contributed to the annual value of $608000.0 for FY2024, which is 10911.54% up from last year.
  • As of Q3 2025, Rockwell Medical's EBITDA stood at -$1.6 million, which was down 18181.82% from -$1.3 million recorded in Q2 2025.
  • Rockwell Medical's 5-year EBITDA high stood at $1.9 million for Q3 2024, and its period low was -$8.4 million during Q4 2021.
  • For the 5-year period, Rockwell Medical's EBITDA averaged around -$3.0 million, with its median value being -$1.7 million (2023).
  • Its EBITDA has fluctuated over the past 5 years, first skyrocketed by 21145.65% in 2024, then tumbled by 36194.17% in 2025.
  • Over the past 5 years, Rockwell Medical's EBITDA (Quarter) stood at -$8.4 million in 2021, then soared by 76.48% to -$2.0 million in 2022, then surged by 72.18% to -$547000.0 in 2023, then increased by 5.12% to -$519000.0 in 2024, then tumbled by 205.2% to -$1.6 million in 2025.
  • Its last three reported values are -$1.6 million in Q3 2025, -$1.3 million for Q2 2025, and -$1.4 million during Q1 2025.